Skip to Main Content

Paper Details

A Preclinical Assessment of <sup>89</sup>Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with <sup>89</sup>Zr-C4.
Bioconjug Chem
33
2018
Author NameAffiliation
Natalia SevillanoDepartment of Pharmaceutical Chemistry , University of California san francisco
Charles S CraikDepartment of Pharmaceutical Chemistry , University of California san francisco
  • 1 - 2

Datasets

Release 1.2